✦ LIBER ✦

Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide

✍ Scribed by Thomas L. Seck; Samuel S. Engel; Debora E. Williams-Herman; Christine McCrary Sisk; Gregory T. Golm; Hongwei Wang; Keith D. Kaufman; Barry J. Goldstein

Book ID: 116407097
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 249 KB
Volume: 93
Category: Article
ISSN: 0168-8227
DOI: 10.1016/j.diabres.2011.03.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vildagliptin more effectively achieves a

Vildagliptin more effectively achieves a composite endpoint of HbA1c<7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment

✍ Bader, Giovanni; Geransar, Parnia; Schweizer, Anja 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 306 KB

Linagliptin is more effective than glime

Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA 1c < 7% with no hypoglycaemia and no weight gain over 2 years

✍ Gallwitz, B.; Rosenstock, J.; Emser, A.; von Eynatten, M.; Woerle, H.-J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB